Medical Condition News

RSS

Heavy alcohol intake can lead to increased risk of AF

Atrial Fibrillation is the most common cardiac arrhythmia. Its name comes from the fibrillating of the heart muscles of the atria, instead of a coordinated contraction. The result is an irregular heartbeat, which may occur in episodes lasting from minutes to weeks, or it could occur all the time for years. Atrial fibrillation alone is not in itself generally life-threatening, but it may result in palpitations, fainting, chest pain, or congestive heart failure.

14 Feb 2011

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it received the interim report of its phase 2-3 trial to treat Alpha-1 deficiency with its flag product, Alpha-Antitrypsin, delivered by inhalation.

14 Feb 2011

NatureBright's light therapy product recommended for relieving Seasonal Affective Disorder

The light therapy product Sun Touch Plus from NatureBright has been recommended by Dr. Chris Idzikowski from the Edinburgh Sleep Centre for relieving Seasonal Affective Disorder (SAD). Dr. Idzikowski is a pioneer in the area of sleep science and chairs the British Sleep Society.

14 Feb 2011

FDA waives NDA filing fee for Antares' Anturol NDA

Antares Pharma, Inc. today announced the receipt from the U.S. Food and Drug Administration (FDA) of a waiver, on February 8, 2011, for the $1,500,000 New Drug Application (NDA) filing fee for Anturol® Gel for overactive bladder (OAB).

14 Feb 2011

FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's NurOwn™ autologous adult stem cell product candidate for the treatment of amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's Disease.

14 Feb 2011

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported that patient enrollment and dosing in the Phase II trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan, with study completion targeted for mid-year 2011.

14 Feb 2011

SpineSmith to rollout VisuALIF stand alone device for intervertebral body fusion of lumbar spine

SpineSmith, a Texas-based medical device company, today announces the company will begin the national rollout in March of the VisuALIF, following a successful Alpha launch.

14 Feb 2011

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

AVEO Pharmaceuticals, Inc. today announced that previously reported positive clinical data evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC) will be featured in several poster presentations at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17-19, 2011 at the Orlando World Center Marriott in Orlando, Fla.

14 Feb 2011

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fifth scheduled safety analysis and recommended that the trial continue per the protocol.

14 Feb 2011

FDA accepts King's ACUROX NDA for filing with Priority review classification

Acura Pharmaceuticals, Inc. today announced that it has been informed by King Pharmaceuticals Research and Development Inc. (King) that King's New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets was accepted for filing by the US Food and Drug Administration (FDA) with a Priority review classification and a Prescription Drug User Fee Act (PDUFA) date of June 17, 2011.

14 Feb 2011

Registration open for idiopathic pulmonary fibrosis healthcare summit

The Pulmonary Fibrosis Foundation (PFF) announced today that registration is now open for the IPF Summit 2011: From Bench to Bedside. The conference will feature an innovative two-day continuing medical education (CME) program for physicians, researchers, and other health care professionals. Additionally there will be a separate one-day patient, family member, and caregiver program to address the growing educational needs of the idiopathic pulmonary fibrosis (IPF) community.

14 Feb 2011

Less than one-third of acute stroke patients receive clot-busting drug within 60 minutes of hospital arrival

Every minute counts after the onset of a stroke. The more time that elapses before a patient receives an intravenous drug to help break up the clot that is blocking a blood vessel in the brain, the slimmer the chances of a good outcome.

14 Feb 2011

World's earliest functional prosthetic body parts on Egyptian mummy

Two artificial big toes - one found attached to the foot of an ancient Egyptian mummy - may have been the world's earliest functional prosthetic body parts, says the scientist who tested replicas on volunteers.

14 Feb 2011

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P."

14 Feb 2011

Expensive 'high tech' therapy not superior to home training for walking recovery of stroke survivors

Home-based physical therapy to improve the strength and balance of stroke survivors works about as well to get them walking again as treadmill training done in a physical therapy lab, according to the results of a study presented today by a Duke researcher at the American Stroke Association's International Stroke Conference.

14 Feb 2011

Novel technology to diagnose Alzheimer's disease before symptoms appear

UT Southwestern Medical Center scientists have helped develop a novel technology to diagnose Alzheimer's disease from blood samples long before symptoms appear.

14 Feb 2011

Study: Young survivors covered by Medicare Part D often can't afford stroke medications

Young, uninsured stroke survivors or those covered by the Medicare Part D drug benefit often can't afford medications - increasing the risk for future strokes or other cardiovascular disease-related events, according to research presented at the American Stroke Association's International Stroke Conference 2011.

14 Feb 2011

JDR releases research report on Osteonecrosis of the jaw

Osteonecrosis of the jaw is a debilitating bone condition that affects the jaws and occurs as a result of reduced local blood supply to the bone. The literature in this area has been severely limited since most investigations cannot evaluate sufficient numbers of afflicted individuals to accurately determine the incidence of the disease and associated risk factors.

14 Feb 2011

Phase III RISE study of Lucentis for DME meets primary endpoint

Genentech, Inc., a member of the Roche Group, announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness.

14 Feb 2011

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company and its interferon payload technology platform and drug discovery pipeline is featured in the February 7 issue of BioCentury, one of the most widely read publications in the pharma and biotech industries.

14 Feb 2011

Medical Condition News

Heavy alcohol intake can lead to increased risk of AF

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

NatureBright's light therapy product recommended for relieving Seasonal Affective Disorder

FDA waives NDA filing fee for Antares' Anturol NDA

FDA grants BrainStorm's NurOwn orphan drug designation for treatment of ALS

PROLOR reports positive DSMB review of long-acting human growth hormone clinical trial

SpineSmith to rollout VisuALIF stand alone device for intervertebral body fusion of lumbar spine

Positive clinical data of AVEO's tivozanib featured at 2011 ASCO Genitourinary Cancers Symposium

Independent Safety Monitoring Board recommends Vical's Allovectin-7 Phase 3 trial to continue as per protocol

FDA accepts King's ACUROX NDA for filing with Priority review classification

Registration open for idiopathic pulmonary fibrosis healthcare summit

Less than one-third of acute stroke patients receive clot-busting drug within 60 minutes of hospital arrival

World's earliest functional prosthetic body parts on Egyptian mummy

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Expensive 'high tech' therapy not superior to home training for walking recovery of stroke survivors

Novel technology to diagnose Alzheimer's disease before symptoms appear

Study: Young survivors covered by Medicare Part D often can't afford stroke medications

JDR releases research report on Osteonecrosis of the jaw

Phase III RISE study of Lucentis for DME meets primary endpoint

BioCentury features ImmunGene's interferon payload technology and cancer antibodies

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News